The neuroprotective role of erythropoietin in the management of acute ischaemic stroke: from bench to bedside

Recombinant human erythropoietin was produced soon after the discovery of the erythropoietin gene in 1985 and since then, it is used in various clinical conditions such as chronic renal failure. Moreover, experimental studies have shown that erythropoietin exerts neuroprotective action as well. Rece...

Full description

Saved in:
Bibliographic Details
Published inActa neurologica Scandinavica Vol. 118; no. 6; pp. 362 - 366
Main Authors Ntaios, G., Savopoulos, C., Chatzinikolaou, A., Hatzitolios, A. I.
Format Journal Article
LanguageEnglish
Published Oxford, UK Blackwell Publishing Ltd 01.12.2008
Blackwell
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Recombinant human erythropoietin was produced soon after the discovery of the erythropoietin gene in 1985 and since then, it is used in various clinical conditions such as chronic renal failure. Moreover, experimental studies have shown that erythropoietin exerts neuroprotective action as well. Recently, a clinical trial yielded promising results concerning the use of erythropoietin in stroke management. In this review, we summarize the main data which suggest that recombinant human erythropoietin and its analogues may indeed have a role in stroke treatment.
Bibliography:istex:051E140359F92D87C7DDE3A983C699F6B6DC9FE0
ArticleID:ANE1039
ark:/67375/WNG-RSLX5BRB-W
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Feature-3
ObjectType-Review-1
ISSN:0001-6314
1600-0404
DOI:10.1111/j.1600-0404.2008.01039.x